IPH5201
Gecertificeerd

IPH5201

Catalog #: HY-P991444
Maat: 1 Each

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100

Technische Specificaties

Description

IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control.

UNSPSC

12352203

Target

NTPDase

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

I[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5]

References & Citations

[1]Barlesi F, et al. 1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE) [J]. Annals of Oncology, 2023, 34: S744.

Shipping Conditions

Room temperature

Product MSDS

http://file.medchemexpress.com/batch_PDF/HY-P991444/

Scientific Category

Inhibitory Antibodies

Clinical Information

No Development Reported

Beschrijving

IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combinat

Specificaties

ProductnaamIPH5201
Categorie
Beschikbare grootte1 Each
CatalogusnummerHY-P991444